On the occasion of "International Women's Day 2025", our company Wang Yuchairman of the boardFor her outstanding leadership and contribution to scientific research, she was honored with the title of "Beijing March 8 Red Flag Woman". This award was established by the Beijing Women's Federation to recognize women who have made outstanding achievements and demonstrated outstanding influence in various fields. This award not only demonstrates the society's highest recognition of President Wang Yu's personal achievements, but also highlights Darwin Bio's innovative strength in the field of nerve repair and life health.
Today, at this glorious moment, let us enter the world of this outstanding female research leader, and witness together how "her power" leads to continuous breakthroughs in biotechnology and writes a new chapter for the protection of human health.
From the lab to the clinic: "Life guardians".
Under the outstanding leadership of Chairman Wang Yu, Darwin Cell Biotechnology has always been committed to the cutting-edge exploration in the field of nerve repair, and is determined to overcome the medical problems of acromegaly (ALS), stroke, Alzheimer's disease and other neurodegenerative diseases.
Innovative breakthroughs: The company's self-developed Class 1 bio-innovation drug "Alitol" has shown revolutionary efficacy in the treatment of related diseases, and in December 2023, Darwin Cellular Biotechnology and Tiantan Hospital jointly launched the "Clinical Study on the Treatment of Amyotrophic Lateral Sclerosis ("SPECIALS")", and in September 2024, jointly established the "Joint Laboratory of Translational Technology for Acromegaly and Nerve Repair". In September 2024, Darwin Cell Biotechnology and Tiantan Hospital jointly established the "Joint Laboratory for Translational Transformation of Acute Lateral Sclerosis and Neural Repair Technology", and in February 2025, Darwin Cell Biotechnology and Tiantan Hospital officially launched the "Clinical Study on Alito for Acute Ischemic Stroke (ASSIST)", which will provide a new opportunity for rare diseases to be treated.) In February 2025, we officially launched the "Alito Clinical Study for Acute Ischemic Stroke (ASSIST)", which opens up a whole new horizon for the treatment of rare diseases and other neurodegenerative diseases.
Social Responsibility: In addition to scientific breakthroughs, Darwin Bio also actively fulfills its social responsibility by donating to the "Wings of the Wind" public welfare program of the Beijing Foundation for the Development of Women and Children. In addition, Chairman Wang Yu led the establishment of Beijing Darwin Cell Biotechnology Co., Ltd. Science and Technology Association, in order to strengthen the cooperation of all parties, to promote the deep integration of industry, academia, research and utilization, and to promote the synergistic development of the industry. Chairman Wang Yu emphasized: "Science and technology should not only exist in the papers, but should also be turned into effective medicine in the hands of patients."
Women's Power: Writing "Hardcore Tenderness" on the Biotech Circuit
Scientific Leadership: In the field of biopharmaceuticals, President Wang Yu has become a model for outstanding female leaders with her unique perspective and strong beliefs. She advocates the integration of rigorous scientific spirit and profound humanistic care, and has led the company to set up an international high-level scientific research team and build a nationally certified GMP laboratory.
Inspiring women's potential: She advocates "inclusive innovation" and encourages more women to join the scientific field. Currently, the proportion of female researchers in the company has reached 45%, covering the entire chain from basic research to production and translation.
English 
Chinese